The Effectiveness of Nivolumab (OPDIVO®) Monotherapy as First-Line Therapy in Adults With Advanced (Unresectable or Metastatic) Melanoma: An Early Retrospective, Observational Study in Germany
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 Sep 2017 Planned End Date changed from 15 Dec 2017 to 31 Jan 2018.
- 01 Sep 2017 Planned primary completion date changed from 15 Dec 2017 to 31 Jan 2018.
- 01 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 1 Nov 2017.